Summary: Incannex Healthcare Inc provided an update on its lead drug candidate, IHL-42X, an oral therapy in development for the treatment of obstructive sleep apnea (OSA), highlighting progress in its phase 2/3 clinical trial. The clinical trial aims to evaluate IHL-42X in OSA … [Read more...]
Early Insomnia Drug Chloral Hydrate Shows Renewed Potential in Severe Cases
Summary: Pharmanovia, in partnership with Lindus Health, announced positive topline results from its open-label RESTORE trial on chloral hydrate for severe insomnia. The trial, which involved 100 adult patients receiving chloral hydrate over 14 days, demonstrated improvements in … [Read more...]
Epilepsy Drug Slashes Breathing Pauses in OSA Patients
Summary: A clinical trial presented at the European Respiratory Society Congress in Vienna revealed that the epilepsy drug sulthiame significantly reduced symptoms of obstructive sleep apnea (OSA) in patients who cannot tolerate CPAP therapy. The study, conducted across multiple … [Read more...]
Drug Can Restore Brain’s Waste-Clearing Ability in Aging Mice
Summary: New research has demonstrated that a known drug can restore the brain’s ability to clear toxic waste in aging mice, a process that slows down with age and contributes to the development of neurological diseases like Alzheimer’s and Parkinson’s. The study, published in … [Read more...]
Avadel Eyes New Indications for Narcolepsy Drug Lumryz
Summary: Avadel Pharmaceuticals announced its second-quarter results, highlighting the progress of its narcolepsy drug, Lumryz. The company initiated a phase 3 trial for Lumryz in idiopathic hypersomnia and awaits an FDA decision on its use in pediatric narcolepsy. Lumryz, … [Read more...]
Incannex Sleep Apnea Drug Trial: Key Findings
Summary: Incannex Healthcare has completed dosing in a clinical trial evaluating the bioavailability and bioequivalence of IHL-42X, a combination drug candidate for treating obstructive sleep apnea. The trial compared the bioavailability of IHL-42X’s components, dronabinol and … [Read more...]
EMA Recommends Melatonin Drug for Children with Neurogenetic Disorders
Summary: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Slenyto, a prolonged-release melatonin drug, to treat insomnia in children with neurogenetic disorders. Originally approved in 2018 for children … [Read more...]
Sleep Monitoring Integrated into Phase 2 Obesity Drug Trial
Summary: Beacon Biosignals and Skye Bioscience are partnering to integrate sleep quality and sleep apnea endpoints in a phase 2 trial of obesity drug candidate Nimacimab. The trial will utilize sleep monitoring technology to provide an assessment of the drug’s impact on … [Read more...]
Insomnia Drug Suvorexant Increases Fat Burning During Sleep
Summary: A new randomized, double-blind, placebo-controlled crossover study has found that suvorexant, an orexin receptor antagonist approved for treating insomnia, promotes fat oxidation and reduces protein catabolism during sleep without significantly changing total sleep time. … [Read more...]
FDA Rejects Petition Challenging Safety of Narcolepsy Drug Wakix
Summary: The FDA has denied a citizen petition filed by a short seller challenging the safety and effectiveness of Wakix (pitolisant) for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. The FDA reaffirmed Wakix’s favorable benefit-risk profile and … [Read more...]